BeiGene, Ltd. (BGNE)
NASDAQ: BGNE · Real-Time Price · USD
176.50
+1.78 (1.02%)
At close: Dec 20, 2024, 4:00 PM
177.10
+0.60 (0.34%)
After-hours: Dec 20, 2024, 5:23 PM EST
BeiGene Revenue
BeiGene had revenue of 7.35B CNY in the quarter ending September 30, 2024, with 39.54% growth. This brings the company's revenue in the last twelve months to 23.51B, up 50.22% year-over-year. In the year 2023, BeiGene had annual revenue of 2.46B with 73.65% growth.
Revenue (ttm)
23.51B CNY
Revenue Growth
+50.22%
P/S Ratio
5.50
Revenue / Employee
2,217,710 CNY
Employees
10,600
Market Cap
18.75B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.46B | 1.04B | 73.65% |
Dec 31, 2022 | 1.42B | 239.64M | 20.37% |
Dec 31, 2021 | 1.18B | 867.41M | 280.83% |
Dec 31, 2020 | 308.87M | -119.34M | -27.87% |
Dec 31, 2019 | 428.21M | 229.99M | 116.03% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Molina Healthcare | 37.54B |
Labcorp Holdings | 12.71B |
Quest Diagnostics | 9.54B |
ICON Public Limited Company | 8.31B |
Zimmer Biomet Holdings | 7.60B |
STERIS | 5.33B |
Illumina | 4.39B |
The Cooper Companies | 3.90B |
BGNE News
- 9 days ago - BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor - Business Wire
- 12 days ago - BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets - Business Wire
- 17 days ago - BeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL - Business Wire
- 19 days ago - BeiGene to Host Investor Webcast Highlighting Key Data from ASH and the San Antonio Breast Cancer Symposium on December 16, 2024 - Business Wire
- 20 days ago - BeiGene: Nearing Profitability On TEVIMBRA Approval In The EU And US - Seeking Alpha
- 24 days ago - European Commission Approves BeiGene's TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer - Business Wire
- 25 days ago - BeiGene to Present at Upcoming Investor Conferences - Business Wire
- 4 weeks ago - Labcorp CFO Glenn Eisenberg Announces Plans to Retire - PRNewsWire